Implantable cardioverter-defibrillators in congenital heart disease.

Abstract

Implantable cardioverter-defibrillators (ICD) have an important role in reducing sudden cardiac death in patients with congenital heart disease (CHD); however, the benefit of ICDs needs to be weighed up against both short-term and long-term adverse effects, which are difficult to evaluate in the heterogeneous CHD population. A tailored approach, taking into account risk stratification and patient-specific factors, is needed to select the most appropriate strategy. This review discusses primary and secondary ICD indications, implantation approaches and long-term follow-up. Recent publications have shed light on the concerns of system longevity, lead extractions, inappropriate shocks and impact on the quality of life. All of these factors require consideration prior to commitment to this long-term treatment strategy.

• Authors: H Chubb, E Rosenthal
• Journal: Herzschrittmachertherapie & Elektrophysiologie (Herzschrittmacherther Elektrophysiol) Vol. 27 Issue 2 Pg. 95-103 (Jun 2016) ISSN: 1435-1544 [Electronic] Germany
• Vernacular Title: Implantierbare Kardioverter-Defibrillatoren bei angeborenem Herzfehler.
• PMID: 27250725 (Publication Type: Journal Article, Review)

Topics

• Adult
• Death, Sudden, Cardiac (prevention & control)
• Defibrillators, Implantable
• Evidence-Based Medicine
• Female
• Heart Defects, Congenital (complications, diagnosis, therapy)
• Humans
• Male
• Prognosis
• Symptom Assessment (methods)
• Tachycardia, Ventricular (diagnosis, etiology, prevention & control)
• Treatment Outcome